SIBN SI-BONE, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1459839 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.0%
TTM net income YoY37.1%
TTM EPS YoY39.2%
Revenue 3-yr CAGR18.7%
Net income 3-yr CAGR—
Margins
Gross margin79.4%
Operating margin-7.6%
Net margin-6.2%
FCF margin-1.9%
EBITDA margin-4.6%
Returns
ROE-7.7%
ROA-5.6%
ROIC (approx.)-7.2%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets28.1%
Debt / equity0.19x
Current ratio7.58x
Interest coverage-6.88x
Cash quality & payout
Operating cash flow / net income-0.44x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $55.70M | $56.01M | $52.59M | $56.35M | $48.66M | $48.63M | $47.29M | $49.00M |
| Cost of revenue | $11.54M | $11.46M | $10.64M | $11.82M | $9.81M | $9.82M | $9.60M | $10.22M |
| Gross profit | $44.17M | $44.55M | $41.94M | $44.53M | $38.85M | $38.81M | $37.70M | $38.78M |
| R&D expense | $4.56M | $5.22M | $4.19M | $4.36M | $4.24M | $4.31M | $4.53M | $3.87M |
| SG&A expense | $10.11M | $10.11M | $10.04M | $9.82M | $10.03M | $10.72M | $9.96M | $9.15M |
| Operating income | -$4.35M | -$4.81M | -$5.09M | -$2.46M | -$5.38M | -$7.00M | -$7.48M | -$5.49M |
| Interest expense | $608,000 | $598,000 | $592,000 | $630,000 | $670,000 | $666,000 | $662,000 | $793,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.62M | -$4.09M | -$4.33M | -$1.64M | -$4.57M | -$6.15M | -$6.54M | -$4.50M |
| EBITDA | -$2.65M | -$3.11M | -$3.48M | -$825,000 | -$3.88M | -$5.60M | -$6.20M | -$4.28M |
| EPS (basic) | -0.08 | -0.09 | -0.10 | — | -0.11 | -0.14 | -0.15 | — |
| EPS (diluted) | -0.08 | -0.09 | -0.10 | — | -0.11 | -0.14 | -0.15 | — |
| Weighted avg. shares (diluted) | 44.90M | 44.48M | 43.96M | — | 43.19M | 42.79M | 42.34M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $35.31M | $33.13M | $33.53M | $42.24M | $26.49M | $34.15M | $41.19M | $34.95M |
| Receivables | $31.47M | $31.18M | $30.96M | $29.91M | $26.53M | $24.37M | $26.70M | $27.46M |
| Inventory | $42.35M | $38.39M | $35.53M | $33.90M | $35.73M | $34.24M | $30.38M | $27.07M |
| Current assets | $224.65M | $219.91M | $214.72M | $216.12M | $210.78M | $207.45M | $204.20M | $207.78M |
| PP&E, net | $25.30M | $21.72M | $20.45M | $21.30M | $21.93M | $21.70M | $21.07M | $20.37M |
| Total assets | $256.77M | $248.76M | $242.72M | $238.56M | $234.27M | $230.92M | $227.28M | $230.44M |
| Current liabilities | $29.62M | $24.04M | $21.49M | $25.28M | $26.44M | $24.75M | $23.95M | $27.13M |
| Long-term debt | $35.66M | $35.63M | $35.60M | $35.57M | $35.54M | $35.51M | $35.48M | $35.45M |
| Total debt | $35.66M | $35.63M | $35.60M | $35.57M | $35.54M | $35.51M | $35.48M | $35.45M |
| Total liabilities | $72.09M | $66.41M | $63.78M | $61.02M | $62.15M | $60.58M | $60.02M | $63.47M |
| Shareholders' equity | $184.68M | $182.35M | $178.94M | $177.53M | $172.13M | $170.34M | $167.26M | $166.96M |
| Net debt | $346,000 | $2.50M | $2.06M | -$6.67M | $9.05M | $1.36M | -$5.71M | $504,000 |
| Shares outstanding | 45.00M | 44.70M | 44.20M | 43.65M | 43.27M | 43.01M | 42.48M | 42.09M |
| Cash flow statement | ||||||||
| Operating cash flow | $5.94M | $777,000 | -$2.36M | $1.73M | $2.33M | $173,000 | -$4.91M | $1.18M |
| Capital expenditure | $6.37M | $1.54M | $1.08M | $1.29M | $2.96M | $2.10M | $2.07M | $2.27M |
| Free cash flow | -$427,000 | -$768,000 | -$3.44M | $440,000 | -$620,000 | -$1.93M | -$6.98M | -$1.09M |
| Investing cash flow | -$4.08M | -$2.74M | -$6.23M | $13.03M | -$10.03M | -$9.47M | $10.63M | $4.34M |
| Financing cash flow | $347,000 | $1.63M | $34,000 | $1.03M | $11,000 | $2.23M | $103,000 | -$78,000 |
| Depreciation & amortization | $1.70M | $1.70M | $1.62M | $1.64M | $1.50M | $1.40M | $1.28M | $1.21M |
| Stock-based compensation | $5.71M | $5.98M | $6.03M | $5.98M | $6.23M | $6.66M | $6.66M | $6.13M |
Free plan shows the latest 8 periods; Pro shows all 37 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.